AVNS Stock Overview
A medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Avanos Medical, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$19.91 |
52 Week High | US$26.56 |
52 Week Low | US$17.24 |
Beta | 0.97 |
1 Month Change | 5.96% |
3 Month Change | 6.13% |
1 Year Change | -19.81% |
3 Year Change | -49.13% |
5 Year Change | -50.80% |
Change since IPO | -49.91% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Avanos Medical, Inc.'s (NYSE:AVNS) Low P/S
Apr 17Is Avanos Medical (NYSE:AVNS) A Risky Investment?
Jan 05Some Avanos Medical, Inc. (NYSE:AVNS) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 14When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
Aug 13Avanos Medical: Leaning Up, Attractive Returns On Incremental Capital, Reiterate Buy
Jul 16We Think Avanos Medical (NYSE:AVNS) Can Manage Its Debt With Ease
Jun 05Avanos Medical, Inc. (NYSE:AVNS) Stocks Pounded By 26% But Not Lagging Market On Growth Or Pricing
May 18Avanos Medical (NYSE:AVNS) Is Looking To Continue Growing Its Returns On Capital
May 07Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
Mar 02Avanos Medical Q4 2022 Earnings Preview
Feb 20Avanos Medical, Inc. (NYSE:AVNS) Shares Could Be 30% Below Their Intrinsic Value Estimate
Feb 10Why Avanos Medical, Inc. (NYSE:AVNS) Could Be Worth Watching
Jan 13Avanos Medical reports Q3 mixed earnings; reaffirms FY22 guidance
Nov 02Avanos: Recent Entry To Hyaluronic Acid Market Sparks Interesting Debate
Sep 12Avanos Medical Q2 2022 Earnings Preview
Aug 08When Should You Buy Avanos Medical, Inc. (NYSE:AVNS)?
May 28Is Avanos Medical (NYSE:AVNS) Using Too Much Debt?
May 03Is There An Opportunity With Avanos Medical, Inc.'s (NYSE:AVNS) 41% Undervaluation?
Feb 10Should You Think About Buying Avanos Medical, Inc. (NYSE:AVNS) Now?
Dec 21An Intrinsic Calculation For Avanos Medical, Inc. (NYSE:AVNS) Suggests It's 33% Undervalued
Nov 04Avanos Medical (NYSE:AVNS) Takes On Some Risk With Its Use Of Debt
Sep 10The Strong Earnings Posted By Avanos Medical (NYSE:AVNS) Are A Good Indication Of The Strength Of The Business
Aug 10Is There Now An Opportunity In Avanos Medical, Inc. (NYSE:AVNS)?
Jun 30We Think Avanos Medical (NYSE:AVNS) Is Taking Some Risk With Its Debt
Jun 09Avanos Medical Q1 2021 Earnings Preview
May 06Shareholder Returns
AVNS | US Medical Equipment | US Market | |
---|---|---|---|
7D | -0.3% | -0.8% | -0.6% |
1Y | -19.8% | 2.1% | 22.3% |
Return vs Industry: AVNS underperformed the US Medical Equipment industry which returned 1.8% over the past year.
Return vs Market: AVNS underperformed the US Market which returned 21.5% over the past year.
Price Volatility
AVNS volatility | |
---|---|
AVNS Average Weekly Movement | 3.9% |
Medical Equipment Industry Average Movement | 7.9% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.7% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: AVNS has not had significant price volatility in the past 3 months.
Volatility Over Time: AVNS's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 3,771 | Joe Woody | avanos.com |
Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems.
Avanos Medical, Inc. Fundamentals Summary
AVNS fundamental statistics | |
---|---|
Market cap | US$857.18m |
Earnings (TTM) | -US$1.60m |
Revenue (TTM) | US$680.10m |
1.3x
P/S Ratio-537.1x
P/E RatioIs AVNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AVNS income statement (TTM) | |
---|---|
Revenue | US$680.10m |
Cost of Revenue | US$297.00m |
Gross Profit | US$383.10m |
Other Expenses | US$384.70m |
Earnings | -US$1.60m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.037 |
Gross Margin | 56.33% |
Net Profit Margin | -0.24% |
Debt/Equity Ratio | 14.4% |
How did AVNS perform over the long term?
See historical performance and comparison